Advertisement
UK markets close in 6 hours 3 minutes

  • FTSE 100

    8,361.40
    +7.35 (+0.09%)
     

  • FTSE 250

    20,489.36
    -2.63 (-0.01%)
     

  • AIM

    781.72
    +1.89 (+0.24%)
     

  • GBP/EUR

    1.1627
    +0.0004 (+0.04%)
     

  • GBP/USD

    1.2475
    -0.0023 (-0.18%)
     

  • Bitcoin GBP

    48,890.63
    -997.21 (-2.00%)
     

  • CMC Crypto 200

    1,321.53
    +21.43 (+1.65%)
     

  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • CRUDE OIL

    79.55
    +0.56 (+0.71%)
     

  • GOLD FUTURES

    2,316.80
    -5.50 (-0.24%)
     

  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     

  • HANG SENG

    18,537.81
    +223.95 (+1.22%)
     

  • DAX

    18,551.57
    +53.19 (+0.29%)
     

  • CAC 40

    8,122.13
    -9.28 (-0.11%)
     
Money:

Bank of England expected to hold interest rates

Investors predict MPC will maintain interest at 5.25% when it meets on Thursday.

STOCKS NEWS EUROPE-UCB falls after weak Cimzia sales

Reuters - UK Focus

Shares in UCB (Other OTC: UCBJY - news) fall as much as 4.3 percent after the Belgian pharma group reports lower than expected sales of its new rheumatoid arthritis and Crohn's disease drug Cimzia.

"The numbers were a bit below consensus. Sales of Cimzia were quite weak and there's more sales erosion from generic competition for Keppra," a Brussels-based trader said.

At 1045 GMT, UCB's shares are 3 percent lower, making them the weakest performers on the STOXX European Healthcare Index which trades broadly unchanged.

For more on UCB's results , please click Reuters messaging rm://robertjan.bartunek.thomsonreuters.com@reuters.net